The ALDH1A1 Knockout 769-P Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population in which the human ALDH1A1 gene has been disrupted in the 769-P cell background. This ablative model is designed for loss-of-function studies of ALDH1A1-mediated aldehyde metabolism and retinoic acid signaling. The polyclonal format preserves genetic heterogeneity, enabling assessment of gene disruption effects across a diverse cell population without clonal selection bias. Researchers can employ these cells to dissect the enzymatic and non-enzymatic roles of ALDH1A1 in cellular homeostasis and pathological contexts.
The 769-P host cell line is an adherent epithelial line originally derived from a primary human clear cell renal cell carcinoma (ccRCC). It retains key features of renal carcinoma, including characteristic morphology and tumorigenic potential, and is widely used as a model system for ccRCC biology. This cell line exhibits activation of pathways commonly dysregulated in kidney cancer, such as HIF-1?? and TGF-?? signaling, making it a relevant platform for interrogating ALDH1A1 function in renal oncogenesis.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that irreversibly oxidizes retinaldehyde to all-trans-retinoic acid (atRA), a ligand for nuclear retinoic acid receptors (RAR/RXR). Binding of atRA activates RAR/RXR heterodimers to regulate gene transcription. ALDH1A1 is transcriptionally activated by SOX2, OCT4, and NANOG, and atRA signaling reciprocally maintains their expression. The pathway converges with Wnt/??-catenin signaling via Wnt ligands and atRA-mediated modulation of ??-catenin activity. Downstream, CYP26A1 degrades atRA, and Bcl-2 is up?regulated. ALDH1A1 acts as a homodimer and interacts with retinol-binding and cellular retinoic acid-binding proteins.
In clear cell renal cell carcinoma, ALDH1A1 expression is correlated with cancer stem cell (CSC) properties, including enhanced tumor?initiating capacity, chemoresistance, and epithelial?mesenchymal plasticity. The 769-P line, with its ccRCC origin and intact retinoic acid machinery, provides a pathophysiologically relevant context to examine how loss of ALDH1A1 affects CSC maintenance, retinoic acid?responsive gene programs, and cross?talk with HIF?1?? and TGF??? pathways that are frequently altered in renal cancer. By eliminating ALDH1A1 activity, this knockout model allows dissection of retinoic acid?dependent versus ?independent functions of the enzyme and its contribution to tumor cell heterogeneity.
These polyclonal knockout cells are suited for flow?cytometric ALDH activity assays, sphere formation, migration/invasion studies, and drug?sensitivity profiling. Transcriptomic and proteomic analyses (RNA?seq, RT?qPCR, Western blot) can map retinoic acid?responsive networks. This model enables dissection of cancer stem cell biology and therapy resistance mechanisms in renal carcinoma. For more information, contact Ascent Research.
